4. When the superficial inguinal lymph nodes are retracted over the fascia lata from the craniolateral part, the fossa ovalis is identified at the central part of the incision, which is covered by the cribriform fascia. Besides, during the excision of the superficial nodes at the caudal part of this area, the great saphenous vein passing through the fossa ovalis is identified.

5. After total excision of the superficial inguinal lymph nodes, the cribriform fascia is dissected. The femoral vein is identified below the fascia lata, covered by the femoral sheath between the sartorius muscle laterally and the adductor longus muscle medially. The great saphenous vein drains into the femoral vein, and the deep inguino-femoral lymph nodes, which are located medial to the femoral vein, are dissected. The femoral artery lies at the lateral part of the femoral vein, and the femoral nerve is the most lateral component in the femoral sheath.

6. The deep inguino-femoral lymph nodes cover the base of the great saphenous vein.

7. During excision of the deep inguino-femoral lymph nodes, the deep external pudendal vein should also be kept in mind, which drains into the great saphenous or femoral vein.

Conclusion* The essential anatomy of the superficial inguinal and deep femoral lymph nodes, with Scarpa's fascia, fascia lata of the thigh, and cribriform fascia should be known to perform an inguino-femoral lymphadenectomy.

Late breaking abstracts

Cervical cancer

58

KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER

¹N Colombo*, ²C Dubot, ³D Lorusso, ⁴V Caceres, ⁵K Hasegawa, ⁶R Shapira-Frommer, ⁷K Tewari, ⁸P Salman, ⁹E Hoyos Usta, ¹⁰E Yañez, ¹¹M Gümüş, ¹²M Olivera Hurtado de Mendoza, ¹³V Samouëlian, ¹⁴V Castonguay, ¹⁵A Arkhipov, ¹⁶S Toker, ¹⁶K Li, ¹⁶S Keefe, ¹⁷B Monk. ¹University of Milan-Bicocca and European Institute of Oncology (IEO) IRCCS, Milan, Italy; ²Institut Curie Saint-Cloud, Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Saint-Cloud, France; ³Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy; ⁴Institute of Oncology Angel H. Roffo, Buenos Aires, Argentina; ⁵Saitama Medical University International Medical Center, Hidaka, Japan; ⁶Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel; ⁷University of California Irvine, Irvine, USA; ⁸Oncovida Cancer Center, Providencia, Chile; ⁹Imat Oncomedica S.A., Montería, Colombia; ¹⁰Universidad de La Frontera, Temuco, Chile; ¹¹Istanbul Medeniyet University Hospital, Istanbul, Turkey; ¹²Instituto Nacional de Enfermedades Neoplásicas, Medical Oncology, Lima, Peru; ¹³Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche de l'Université de Montréal (CRCHUM), Université de Montréal, Montreal, Canada; ¹⁴Centre Hospitalier Universitaire de Québec, Université Laval, Québec City, Canada; ¹⁵Medical Rehabilitation Center under the Ministry of Health of Russian Federation, Moscow, Russian Federation; ¹⁶Merck and Co., Inc., Kenilworth, USA; ¹⁷Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, USA

10.1136/ijgc-2021-ESGO.641

Introduction/Background* Pembrolizumab has efficacy in previously treated, PD-L1-positive advanced cervical cancer. KEYNOTE-826 (NCT03635567) was a phase 3, randomised, double-blind trial of pembrolizumab or placebo added to chemotherapy ± bevacizumab for first-line treatment of recurrent, persistent, or metastatic cervical cancer.

Methodology Eligible adults had persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy and not amenable to curative treatment. Patients were randomised 1:1 to pembrolizumab 200 mg or placebo Q3W for ≤35 cycles added to chemotherapy (paclitaxel plus cisplatin or carboplatin) ± bevacizumab and stratified by metastatic status at diagnosis, planned bevacizumab use, and PD-L1 combined positive score (CPS). Dual primary endpoints were PFS (RECIST v1.1, investigator review) and OS tested sequentially in the CPS ≥1, all-comer, and CPS ≥10 populations.

Result(s)* 617 patients were randomized: 308 to pembrolizumab plus chemotherapy (63.6% with bevacizumab) and 309 to placebo plus chemotherapy (62.5% with bevacizumab); 548 (88.8%) patients had CPS ≥1, 317 (51.4%) had CPS ≥10. At the protocol-specified first interim analysis, pembrolizumab plus chemotherapy ± bevacizumab significantly improved PFS in the CPS ≥1 (median, 10.4 vs 8.2 months; HR, 0.62 [95% CI, 0.50–0.77]; P<0.001), all-comer (10.4 vs 8.2 months; 0.65 [0.53–0.79]; P<0.001), and CPS ≥10 (10.4 vs 8.1 months; 0.58 [0.44–0.77]; P<0.001) populations. OS was also significantly improved in the CPS ≥1 (median, not reached [NR] vs 16.3 months; HR, 0.64 [95% CI, 0.50–0.81]; P<0.001), all-comer (24.4 vs 16.5 months; 0.67 [0.54–0.84]; P<0.001), and CPS ≥10 (NR vs 16.4 months; 0.61 [0.44–0.84]; P=0.001) populations. Benefits were seen in the with and without bevacizumab subgroups. The incidence of grade ≥3 AEs was 81.8% in the pembrolizumab arm and 75.1% in the placebo arm. Anaemia and neutropenia were the most common grade ≥3 AEs (30.3% vs 26.9% and 12.4% vs 9.7%, respectively).

Conclusion* Pembrolizumab plus chemotherapy ± bevacizumab significantly improves OS and PFS in patients with persistent, recurrent, or metastatic cervical cancer. Along with a manageable safety profile, the clinically meaningful survival benefits suggest pembrolizumab plus chemotherapy ± bevacizumab may be a new standard first-line therapy for this population.

1180

IDENTIFYING PREDICTORS OF LYMPH NODE METASTASES IN EARLY-STAGE CERVICAL CANCER BY TRANSFERRING PREDICTION MODELS ACROSS INTERNATIONAL REGISTRIES

¹T Schnack, ^{2,3}H Wenzel*, ^{4,5}A Norberg Hardie, ^{6,7}R Bekkers, ^{4,5}H Falconer, ¹C Høgdall, ^{8,9,10}P Jensen, ^{2,11}V Lemmens, ²F Martin, ³H Nijman, ²M Van der Aa, ²A Moncada-Torres. ¹Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Department of Gynaecology, Copenhagen, Denmark; ²Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Utrecht, Netherlands; ³University Medical Centre Groningen, University of Groningen, Department of Obstetrics and Gynaecology, Groningen, Netherlands; ⁴Karolinska University Hospital, Department of Pelvic Cancer, Stockholm, Sweden; ⁵Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden; ⁶GROW school for oncology and developmental biology, Maastricht University Medical Centre+, Department of Obstetrics and Gynaecology, Maastricht, Netherlands; ⁷Catharina Hospital, Department of Obstetrics and Gynaecology, Eindhoven, Netherlands; ⁸Aarhus University Hospital, Department of Gynaecology, Aarhus, Denmark; ⁹Aarhus University, Institute of Clinical Medicine, Faculty of Health, Aarhus, Denmark; ¹⁰University of Southern Denmark, Clinical Institute, Faculty of Health Sciences, Odense, Denmark; ¹¹Erasmus MC University Medical Centre, Department of Public Health, Rotterdam, Netherlands

10.1136/ijgc-2021-ESGO.642

Introduction/Background* Identifying risk factors for lymph node metastases in early-stage cervical cancer may aid in tailoring treatment. Unfortunately, early-stage cervical cancer research is often hampered by small sample sizes.

A natural solution to increase sample size is to incorporate data from multiple sources, traditionally done through centralization. Unfortunately, this approach presents disadvantages concerning privacy protection. Alternatively, models can be trained in one source and tested in another setting, sharing only the model coefficients (figure 1). This approach does not disclose any privacy-sensitive information. Additionally, external validation provides stronger evidence on the generalizability of the obtained statistical model.

In this study, we used the alternative approach to increase sample size and identify risk factors for postoperative lymph node metastases (pN1) in early-stage cervical cancer.

Methodology We conducted an international observational cohort study using data from the Danish Gynaecologic Cancer Database (DGCD) and the Netherlands Cancer Registry (NCR). We included women diagnosed with early-stage cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma between 2005–2017, who were treated with radical surgery.

We generated two logistic regression models to identify risk factors for pN1. Model A was trained on NCR data and tested with DGCD data, while model B was obtained the

other way around. The performance of each model was assessed using areas under the curve (AUCs).

Result(s)* A total of 2735 patients were included in the analyses.

In model A – trained on data from 1476 Dutch patients and tested with data from 1259 Danish patients – tumour size (odds ratio 1.62; 95% confidence interval [1.37–1.91]), depth of invasion (1.30 [1.12–1.53]) and LVSI (5.13 [3.50–7.52]) were identified as risk factors for pN1, and body mass index as protective factor (0.80 [0.67–0.95]).

In model B, trained on Danish data ($n=1259$) and tested with Dutch data ($n=1476$), tumour size (1.48 [1.23–1.79]), depth of invasion (1.27 [1.04–1.54]) and LVSI (3.85 [2.53–5.86]) were associated with increased risk of pN1.

External validation of model A and B both showed AUCs of 0.78 (figure 2).

Conclusion* Tumour size, depth of invasion and LVSI were identified as risk factors for pN1 in both models.

Separate models, containing either Danish or Dutch data have shown to be valid by privacy-preserving external validation.

Model A

$$\frac{e^{(\beta_0 + \beta_1 x_1 + \dots + \beta_n x_n)}}{1 + e^{(\beta_0 + \beta_1 x_1 + \dots + \beta_n x_n)}}$$

Model B

Abstract 1180 Figure 1 A privacy-preserving alternative to small sample analysis. Model A is trained on data from the NCR and tested on DGCD data. Model B was obtained the other way around. Only model coefficients need to be shared and, thereby, no privacy-sensitive information is disclosed

Abstract 1180 Figure 2 Areas under the curve for two models identifying risk factors for postoperative lymph node metastases in early-stage cervical cancer. **2A:** Model A trained with NCR data, tested on DGCD data; **2B:** Model B trained with DGCD data, tested on NCR data.

1182

RESECTION OF THE UPPER PARACERVICAL LYMPHOVASCULAR TISSUE SHOULD BE A PART OF A PELVIC SENTINEL LYMPH NODE ALGORITHM IN EARLY STAGE CERVICAL CANCER

O Lührs*, L Ekdahl, B Geppert, C Lönnerfors, J Persson. Lund University Faculty of Medicine, Department of Obstetrics and Gynecology, Lund, Sweden

10.1136/ijgc-2021-ESGO.643

Introduction/Background* To investigate the prevalence of lymph nodes and lymph node metastases (LNMs) in the upper paracervical lymphovascular tissue (UPLT) in early stage cervical cancer.

Methodology In this prospective study consecutive women with stage IA1-IB1 cervical cancer underwent a pelvic lymphadenectomy including identification of sentinel nodes (SLNs) as part of a nodal staging procedure in conjunction with a robotic radical hysterectomy (RRH) or robotic radical trachelectomy (RRT). Indocyanine green (ICG) was used as tracer. The UPLT was separately removed and defined as “SLN-parametrium” and, as all SLN tissue, subjected to ultrastaging and immunohistochemistry. Primary endpoint was prevalence of lymph nodes and metastatic lymph nodes in the UPLT. Secondary endpoints were complications associated with removal of the UPLT.

Result(s)* One hundred and forty-five women were analysed. Nineteen (13.1%) had pelvic LNMs, all identified by at least one metastatic SLN. In 76 women (52.4%) at least one UPLT lymph node was identified. Metastatic UPLT lymph nodes were identified in six women of which in three women (2.1% of all women and 15.8% of node positive women) without lateral pelvic LNMs. Thirteen women had lateral pelvic SLN LNMs with either no ($n=5$) or benign ($n=8$) UPLT lymph nodes. No intraoperative complications occurred due to the removal of the UPLT.

Conclusion* Removal of the UPLT should be an integral part of the SLN concept in early stage cervical cancer.